65,437 trials
Traumatic Brain Injury
Primary: Acceptability — 16.68; 17.55; 15.31; 17.25 score on a scale
Cancer Abdomen
Primary: Technical Success — 50 Participants
Pseudomyxoma Peritonei
Primary: Changes in RNA in Tumor Tissues Before and After HIPEC — 1413; 1927 Numbers of changed RNA
Food Selection
Primary: Modified Nutrient Profile Index Score — 50.6; 51.3; 51.3; 50.8 score on a scale
Functional Constipation
Primary: Change From Baseline in Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period — 3.181; 2.503; 0.246; 3.371 SBMs/Week
Analgesics · Gabapentin · Injuries
Primary: Reduction in Opioid Usage — 69.5; 81; 66.3 MME — p=0.687
Healthy Volunteers
Primary: Area Under the Plasma Concentration-time Curve From Time Zero (Predose [Day 1]) to Infinity (AUC) for Zilucoplan — 950930; 932740 hour*nanogram per milliliters (h*ng/mL)
Chronic Low-back Pain
Primary: Change in Back-related Disability at 6-month Post Randomization (Continuous) — -2.1; -3.1; -3.6 change in score from baseline on scale — p=.024
Dental Anxiety
Primary: Pain Score Using Wong-Baker FACES Scale — 2.3; 4.5 Score on a scale
Fibroid Uterus · Pain, Postoperative
Primary: Pain Score — 2; 2; 4 NRS score (0-10 scale)
COVID-19 Testing Behaviors
Primary: Number of Participants Who Self-Reported Use of a COVID-19 Antigen or PCR Test — 31; 22 Participants
Refractory Paroxysmal Atrial Fibrillation
Primary: Percentage of Participants With Long-term Effectiveness — 74.6 Percentage of participants
Breast Cancer Related Lymphedema · Covid19
Primary: COVID-19 Vaccination on Contralateral vs Ipsilateral Arm — 432; 435; 331; 122 Participants
NAFLD · Nonalcoholic Fatty Liver · NASH - Nonalcoholic Steatohepatitis
Primary: Intrahepatic Lipid Content (IHL, Percent Liver Fat) — 3.9 absolute change in percentage liver fat — p=0.4
Advanced or Metastatic Solid Tumors · Non-Hodgkin Lymphoma
Primary: Incidence of Dose Limiting Toxicities (DLTs) — 0; 0; 1 Participants